Sign in →

Test Code TTRX Amyloidosis, Transthyretin-Associated Familial, Reflex, Blood

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Reporting Name

Familial Amyloidosis Reflex

Specimen Type

Whole blood


Shipping Instructions


Specimen must arrive within 4 days of collection. Specimens are stabilized upon receipt and stored until testing is performed.



Specimen Required


Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.


Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK

Specimen Stability Information

Specimen Type Temperature Time
Whole blood Refrigerated (preferred) 4 days
  Ambient  4 days

Specimen Minimum Volume

0.5 mL

Day(s) Performed

Tuesday

Specimen Retention Time

2 months

Report Available

3 to 9 days

Reference Values

An interpretive report will be provided.

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
TTRZ TTR Gene, Full Gene Analysis Yes No

Useful For

Diagnosis of adult individuals suspected of having transthyretin-associated familial amyloidosis

Testing Algorithm

If familial amyloidosis by liquid chromatography-mass spectrometry is abnormal, DNA sequencing will be performed at an additional charge.

 

For more information see Amyloidosis (Familial) Test Algorithm.

CPT Code Information

82542

81404 (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
TTRX Familial Amyloidosis Reflex 94864-6

 

Result ID Test Result Name Result LOINC Value
22668 Wild Type Mass 94860-4
22669 Wild Type Width at Half Height 94863-8
22670 Second Mass 94862-0
22671 Mass Difference 94861-2
22673 Abnormal result 51968-6
50944 Interpretation 69047-9
50946 Reviewed By 18771-6

Method Description

Transthyretin:

Transthyretin (TTR) is purified from plasma using online affinity chromatography coupled to a quadrupole time-of-flight mass spectrometer. The acquired ion spectra are deconvoluted and reviewed for TTR variants. After deconvolution, normal patients present with a single peak corresponding to wildtype (wt) TTR, which serves as a reference. When positive, amyloid patients are typically heterozygous and are detected by the presence of 2 peaks (ie, wt TTR and altered TTR) differing in mass.(Bergen HR 3rd, Zeldenrust SR, Butz ML, et al. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem. 2004;50[9]:1544-1552; Trenchevska O, Yassine HN, Borges CR, et al. Development of quantitative mass spectrometric immunoassay for serum amyloid A. Biomarkers. 2016;21[8]:743-751)

 

TTR Gene Sequencing:

Next generation sequencing (NGS) and/or Sanger sequencing are performed to test for the presence of variants in coding regions and intron/exon boundaries of TTR, as well as some other regions that have known disease-causing variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for deletion-insertions (delins) less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. NGS and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of deletions and duplications in TTR

 

There may be regions of TTR that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences.(Unpublished Mayo method)

 

The reference transcript for TTR gene is NM_000371.3. Reference transcript numbers may be updated due to transcript re-versioning. Always refer to the final patient report for gene transcript information referenced at the time of testing.

Genetics Test Information

Mass spectrometry to evaluate transthyretin (TTR) protein structure is performed first. In all cases demonstrating a structural change, the TTR gene will be further analyzed by DNA sequence analysis. If no alterations are detected, full gene analysis will not be performed unless a specific request for TTRZ / TTR Gene, Full Gene Analysis, Varies is submitted by the ordering healthcare professional or client.

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-Hematopathology/Cytogenetics Test Request (T726)

-Biochemical Genetics Test Request (T798)